| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
This study established a immuno-cell therapy combining activated lymphocytes (NK cells and γδ T cells) and cetuximab, a molecularly targeted drug. As a result of this research, we examined the cytotoxicity of NK cells and γδ T cells against oral cancer cell lines by culturing activated NK cells and γδ T cells. In addition, the synergistic effect of cetuximab was examined in combination with cetuximab. Although activated NK cells and γδ T cells tended to show cytotoxicity against oral cancer cell lines, no clear synergistic effect was observed when cetuximab was used in combination with NK cells and γδ T cells, suggesting the need for careful consideration.
|
